Phathom Pharmaceuticals (PHAT) Corporate presentation summary

Strategic focus and product overview

• Advancing treatments for acid-related disorders with a novel therapy class, PCABs, targeting significant unmet needs in GI care.

• Three FDA-approved products based on vonoprazan, licensed for US, Europe, and Canada, with headquarters in NJ and IL.

• Achieved operating profitability in Q2 2026, with H1 2026 revenues of $132.6M and FY26 guidance of $310–$325M.

Market opportunity and commercial execution

• GERD market in the US treats over 22M patients annually, with ~40% experiencing inadequate relief from PPIs.

• VOQUEZNA is the only FDA-approved PCAB in the US, offering rapid, potent, and durable acid suppression.

• Over 1.7M prescriptions filled, with >80% commercial coverage and >120M lives covered.

• Covered prescriptions grew ~79% YoY to ~209,000 in Q2 2026.

Clinical efficacy and safety

• VOQUEZNA demonstrated superiority to PPIs in Erosive GERD and H. pylori eradication in Phase 3 trials.

• PHALCON-HP and PHALCON-EE trials met primary and key secondary endpoints, showing high eradication and healing rates.

• Safety profiles across trials were consistent with prior studies, with most adverse events mild and comparable to PPIs.